See the DrugPatentWatch profile for xalkori
What does DrugPatentWatch show for Xalkori (crizotinib)?
DrugPatentWatch tracks patent and exclusivity timelines for specific drugs, including Xalkori (crizotinib). Those pages typically summarize:
- Listed patents tied to the product and key jurisdictions
- Patent “expiry” dates and any extension periods
- Data exclusivity / market exclusivity items where available
- Related documents that support the listed dates
To answer precisely (which patents are listed, their expiry dates, and what jurisdictions), I need the exact DrugPatentWatch page you mean or the drug page URL.
How do Xalkori’s patents and exclusivity usually show up on DrugPatentWatch?
On DrugPatentWatch, Xalkori entries are usually presented as a set of “protection” items, each with its own expiration and scope. Users generally look for:
- When the last listed patent protection ends in a given country/region
- Whether data exclusivity still prevents generic or biosimilar entry even after some patents expire
- Whether there are multiple formulations, indications, or filing families that change the effective protection timeline
When would generics potentially enter if patents expire?
If all relevant patent protection and regulatory exclusivity have ended in a region, generic manufacturers can typically pursue approval pathways (the exact timing depends on the country’s regulatory rules and whether any later-expiring patents or exclusivity items still apply).
DrugPatentWatch is mainly used to estimate “earliest possible entry,” not to guarantee it, because:
- Patent litigation or settlements can delay launch
- Regulatory submission timing matters
- Some “evergreening” patents (new formulations, dosing regimens, or additional claims) can extend protection
Are there different Xalkori indications or formulations that change the patent picture?
Sometimes DrugPatentWatch shows multiple patent families for the same branded drug, depending on:
- Different labeled indications
- Different compositions/strengths
- Different claim sets that cover different aspects of the therapy
That can change the “last expiry” date, which is often the date people care about for competition planning.
What I need from you to give the exact DrugPatentWatch details
Send either:
- The DrugPatentWatch link for Xalkori you’re using, or
- The country/region you care about (for example, US, EP, UK) and whether you mean “crizotinib” generally or specifically “Xalkori”
Then I can extract the specific patents/exclusivity items DrugPatentWatch lists for that scope and report their expiry dates.